Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Kassaian, Seyed E ^a   Goodarzynejad, Hamidreza ^a   Boroumand, Mohammad A ^a   Salarifar, Mojtaba ^a   Masoudkabir, Farzad ^b   Mohajeri Tehrani, Mohammad R ^c   Pourhoseini, Hamidreza ^a   Sadeghian, Saeed ^a   Ramezanpour, Narges ^a   Alidoosti, Mohammad ^a   Hakki, Elham ^a   Saadat, Soheil ^b   Nematipour, Ebrahim ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes mellitus; Glycaemic control; Major adverse cardiovascular events; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEMOGLOBIN A1C; HEPARIN; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; CARDIOVASCULAR DISEASE; CORONARY STENT; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE-FREE SURVIVAL; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; IRAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866373555     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-82     Document Type: Article

References (49)

1. Prevention of diabetes mellitus. Report of a WHO study group. World Health Organ Tech Rep Ser 1994, 844:1-100.
2. Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, Bakhai A, Cohen DJ, Kuntz RE, Ho KK. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004, 110:1226-1230. 10.1161/01.CIR.0000140721.27004.4B, 15337693.
3. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA 2005, 293:1501-1508. 10.1001/jama.293.12.1501, 15784875.
4. Lee TT, Feinberg L, Baim DS, Holmes DR, Aroesty JM, Carrozza JP, Cohen DJ, Ho KK, Cutlip DE. Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). Am J Cardiol 2006, 98:718-721. 10.1016/j.amjcard.2006.03.059, 16950169.
5. Ruygrok PN, Webster MW, de Valk V, van Es GA, Ormiston JA, Morel MA, Serruys PW. Clinical and angiographic factors associated with asymptomatic restenosis after percutaneous coronary intervention. Circulation 2001, 104:2289-2294. 10.1161/hc4401.098294, 11696467.
6. Stettler C, Allemann S, Egger M, Windecker S, Meier B, Diem P. Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart 2006, 92:650-657. 10.1136/hrt.2005.070698, 1860952, 16251229.
7. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 2008, 337:a1331. 10.1136/bmj.a1331, 2527175, 18757996.
8. Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, Baumbach A, Angelini G, de Belder A, Oldroyd KG, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010, 55:432-440. 10.1016/j.jacc.2009.10.014, 20117456.
9. Dauerman HL. Percutaneous coronary intervention, diabetes mellitus, and death. J Am Coll Cardiol 2010, 55:1076-1079. 10.1016/j.jacc.2009.09.056, 20079595.
10. Takara A, Ogawa H, Endoh Y, Mori F, Yamaguchi J, Takagi A, Koyanagi R, Shiga T, Kasanuki H, Hagiwara N. Long-term prognosis of diabetic patients with acute myocardial infarction in the era of acute revascularization. Cardiovasc Diabetol 2010, 9:1. 10.1186/1475-2840-9-1, 2815698, 20047694.
11. Kornowski R, Mintz GS, Kent KM, Pichard AD, Satler LF, Bucher TA, Hong MK, Popma JJ, Leon MB. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997, 95:1366-1369. 10.1161/01.CIR.95.6.1366, 9118501.
12. Dunn PJ, Cole RA, Soeldner JS, Gleason RE. Reproducibility of hemoglobin AIc and sensitivity to various degrees of glucose intolerance. Ann Intern Med 1979, 91:390-396.
13. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984, 310:341-346. 10.1056/NEJM198402093100602, 6690962.
14. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444. 10.2337/diacare.16.2.434, 8432214.
15. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 2011, 4:363-371. 10.1161/CIRCOUTCOMES.110.957951, 21586725.
16. Indolfi C, Esposito G, Stabile E, Cavuto L, Pisani A, Coppola C, Torella D, Perrino C, Di Lorenzo E, Curcio A, et al. A new rat model of small vessel stenting. Basic Res Cardiol 2000, 95:179-185. 10.1007/s003950050180, 10879619.
17. Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 2003, 89:218-224. 10.1136/heart.89.2.218, 1767562, 12527687.
18. Indolfi C, Torella D, Cavuto L, Davalli AM, Coppola C, Esposito G, Carriero MV, Rapacciuolo A, Di Lorenzo E, Stabile E, et al. Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. Circulation 2001, 103:2980-2986. 10.1161/01.CIR.103.24.2980, 11413090.
19. Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, Timmis GC, Balasubramaniam M, O'Neill WW. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004, 43:8-14. 10.1016/j.jacc.2003.06.019, 14715174.
20. Briguori C, Condorelli G, Airoldi F, Mikhail GW, Ricciardelli B, Colombo A. Impact of glycaemic and lipid control on outcome after percutaneous coronary interventions in diabetic patients. Heart 2004, 90:1481-1482. 10.1136/hrt.2003.030437, 1768592, 15547037.
21. Ueda H, Mitsusada N, Harimoto K, Miyawaki M, Yasuga Y, Hiraoka H. Glycosylated hemoglobin is a predictor of major adverse cardiac events after drug-eluting stent implantation in patients with diabetes mellitus. Cardiology 2010, 116:51-57. 10.1159/000314331, 20453503.
22. Kasai T, Miyauchi K, Kajimoto K, Kubota N, Kurata T, Daida H. Influence of diabetes on >10-year outcomes after percutaneous coronary intervention. Hear Vessel 2008, 23:149-154.
23. Cicek G, Uyarel H, Ergelen M, Ayhan E, Abanonu GB, Eren M, Gibson CM. Hemoglobin A1c as a prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. Coron Artery Dis 2011, 22:131-137. 10.1097/MCA.0b013e328342c760, 21394027.
24. Corpus RA, O'Neill WW, Dixon SR, Timmis GC, Devlin WH. Relation of hemoglobin A1c to rate of major adverse cardiac events in nondiabetic patients undergoing percutaneous coronary revascularization. Am J Cardiol 2003, 92:1282-1286. 10.1016/j.amjcard.2003.08.008, 14636904.
25. Cefalu WT. Glycemic targets and cardiovascular disease. N Engl J Med 2008, 358:2633-2635. 10.1056/NEJMe0803831, 18539919.
26. Kurukulasuriya LR, Sowers JR. Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc Diabetol 2010, 9:45. 10.1186/1475-2840-9-45, 2940872, 20804556.
27. Liu Y, Yang YM, Zhu J, Tan HQ, Liang Y, Li JD. Prognostic significance of hemoglobin A1c level in patients hospitalized with coronary artery disease. A systematic review and meta-analysis. Cardiovasc Diabetol 2011, 10:98. 10.1186/1475-2840-10-98, 3225330, 22074110.
28. Kitada S, Otsuka Y, Kokubu N, Kasahara Y, Kataoka Y, Noguchi T, Goto Y, Kimura G, Nonogi H. Post-load hyperglycemia as an important predictor of long-term adverse cardiac events after acute myocardial infarction: a scientific study. Cardiovasc Diabetol 2010, 9:75. 10.1186/1475-2840-9-75, 2996353, 21070650.
29. Hasdai D, Rizza RA, Grill DE, Scott CG, Garratt KN, Holmes DR. Glycemic control and outcome of diabetic patients after successful percutaneous coronary revascularization. Am Heart J 2001, 141:117-123. 10.1067/mhj.2001.111957, 11136496.
30. Kauffman AB, Delate T, Olson KL, Cymbala AA, Hutka KA, Kasten SL, Rasmussen JR. Relationship between haemoglobin A1C values and recurrent cardiac events: a retrospective, longitudinal cohort study. Clin Drug Investig 2008, 28:501-507. 10.2165/00044011-200828080-00005, 18598096.
31. Lindsay J, Sharma AK, Canos D, Nandalur M, Pinnow E, Apple S, Ruotolo G, Wijetunga M, Waksman R. Preprocedure hyperglycemia is more strongly associated with restenosis in diabetic patients after percutaneous coronary intervention than is hemoglobin A1C. Cardiovasc Revasc Med 2007, 8:15-20. 10.1016/j.carrev.2006.10.002, 17293264.
32. O'Sullivan CJ, Hynes N, Mahendran B, Andrews EJ, Avalos G, Tawfik S, Lowery A, Sultan S. Haemoglobin A1c (HbA1C) in non-diabetic and diabetic vascular patients. Is HbA1C an independent risk factor and predictor of adverse outcome?. Eur J Vasc Endovasc Surg 2006, 32:188-197. 10.1016/j.ejvs.2006.01.011, 16580235.
33. Lemesle G, Bonello L, de Labriolle A, Maluenda G, Syed AI, Collins SD, Ben-Dor I, Torguson R, Kaneshige K, Xue Z, et al. Prognostic value of hemoglobin A1C levels in patients with diabetes mellitus undergoing percutaneous coronary intervention with stent implantation. Am J Cardiol 2009, 104:41-45. 10.1016/j.amjcard.2009.02.060, 19576319.
34. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853. .
35. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
36. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
37. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139. 10.1056/NEJMoa0808431, 19092145.
38. Ike A, Nishikawa H, Shirai K, Mori K, Kuwano T, Fukuda Y, Takamiya Y, Yanagi D, Kubota K, Tsuchiya Y, et al. Impact of glycemic control on the clinical outcome in diabetic patients with percutaneous coronary intervention-from the FU-registry. Circ J 2011, 75:791-799. 10.1253/circj.CJ-10-0474, 21427500.
39. Marso SP, Mak KH, Topol EJ. Diabetes mellitus: biological determinants of atherosclerosis and restenosis. Semin Interv Cardiol 1999, 4:129-143.
40. Genuth S. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med 1996, 124:104-109.
41. Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am Heart J 1999, 138:S346-S352.
42. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995, 26:57-65. 10.1016/0735-1097(95)00126-K, 7797776.
43. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005, 26:650-661. 10.1093/eurheartj/ehi199, 15728645.
44. Van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003, 31:359-366. 10.1097/01.CCM.0000045568.12881.10, 12576937.
45. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, Pichard AD, Kent KM, Satler LF, Wu H, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998, 32:584-589. 10.1016/S0735-1097(98)00286-1, 9741497.
46. Schofer J, Schluter M, Rau T, Hammer F, Haag N, Mathey DG. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. J Am Coll Cardiol 2000, 35:1554-1559. 10.1016/S0735-1097(00)00574-X, 10807460.
47. Hage C, Norhammar A, Grip L, Malmberg K, Sarkar N, Svane B, Ryden L. Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study. Diab Vasc Dis Res 2009, 6:71-79. 10.1177/1479164109336042, 20368196.
48. Ndrepepa G, Keta D, Byrne RA, Schulz S, Mehilli J, Seyfarth M, Schomig A, Kastrati A. Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention. Hear Vessel 2010, 25:27-34.
49. Schenkeveld L, Magro M, Oemrawsingh RM, Lenzen M, de Jaegere P, van Geuns RJ, Serruys PW, van Domburg RT. The influence of optimal medical treatment on the 'obesity paradox', body mass index and long-term mortality in patients treated with percutaneous coronary intervention: a prospective cohort study. BMJ Open 2012, 2:e000535. 10.1136/bmjopen-2011-000535, 3277907, 22327630.